Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease

References

• Chalmers J, Campling J, Ellsbury G, et al. Community-acquired pneumonia in the United Kingdom: a call to action. Pneumonia. 2017;9(1):15.
   Google Scholar
• Djennad A, Ramsay ME, Pebody R, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine and changes in invasive pneumococcal disease incidence from 2000 to 2017 in those aged 65 and over in England and Wales. EClinicalMedicine. 2018;6:42–50.
   PubMedGoogle Scholar
• Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451.
   PubMed Web of Science ®Google Scholar
• Amin-Chowdhury Z, Collins S, Sheppard C, et al. Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in england: a PROSPECTIVE OBSERVATIONAL COHORT STUDY, 2014–2018. Clinl Infect Dis. 2020;71(8):e235–e243.
   PubMed Web of Science ®Google Scholar
• Hyams C, Begier E, Gonzalez MG Incidence of acute lower respiratory tract disease hospitalisations, including pneumonia, among adults in Bristol, UK, 2019, estimated using both a prospective and retrospective methodology. BMJ Open. 2022 Jun 15;12(6):e057464. DOI: 10.1136/bmjopen-2021-057464.
   PubMed Web of Science ®Google Scholar
• Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013–18. Thorax. 2020;75(1):38–49.
   PubMed Web of Science ®Google Scholar
• Myint PK, Hawkins KR, Clark AB, et al. Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort. Epidemiol Infect. 2016;144(4):803–809.
   PubMed Web of Science ®Google Scholar
• Averin A, Shaff M, Weycker D, et al. Mortality and readmission in the year following hospitalization for pneumonia among US adults. Respir Med. 2021;185:106476.
   PubMed Web of Science ®Google Scholar
• NHS Digital. Hospital Admitted Patient Care Activity 2019-20. 2020.
   Google Scholar
• Health and Social Care Public Health Agency. Changes to the infant pneumococcal conjugate vaccine schedule: information for healthcare practitioners. 2019.
   Google Scholar
• Boccalini S, Bechini A, Levi M, et al. Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Hum Vaccin Immunother. 2013;9(3):699–706.
   PubMed Web of Science ®Google Scholar
• Cho B-H, Stoecker C, Link-Gelles R, et al. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions. Vaccine. 2013;31(50):6011–6021.
   PubMed Web of Science ®Google Scholar
• Evers SMAA, Ament AJHA, Colombo GL, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis. 2007;26(8):531–540.
   PubMed Web of Science ®Google Scholar
• Fry AM, Zell ER, Schuchat A, et al. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine. 2002;21(3):303–311.
   PubMed Web of Science ®Google Scholar
• Heo JY, Seo YB, Choi WS, et al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLOS ONE. 2017;12(5):e0177342.
   PubMed Web of Science ®Google Scholar
• S-l H, Kondo M, Okubo I. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan. PLOS ONE. 2015;10(10):e0139140.
   PubMed Web of Science ®Google Scholar
• Johnstone J, Marrie TJ, Eurich DT, et al. Effect of pneumococcal vaccination in hospitalized adults with community-Acquired Pneumonia. Arch Internal Med. 2007;167(18):1938–1943.
   PubMedGoogle Scholar
• Kuhlmann A, Theidel U, Pletz MW, et al. Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany. Health Econ Rev. 2012;2(1):4.
   PubMedGoogle Scholar
• Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013; 1. DOI:10.1002/14651858.CD000422.pub3.
   PubMed Web of Science ®Google Scholar
• Örtqvist Å, Hedlund J, Burman L-Å, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet. 1998;351(9100):399–403.
   PubMed Web of Science ®Google Scholar
• Simberkoff MS, Cross AP, Al-Ibrahim M, et al. Efficacy of Pneumococcal Vaccine in High-Risk Patients. N Engl J Med. 1986;315(21):1318–1327.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, et al. Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in U.S. Old Adults Am J Prev Med. 2013;44(4):373–381.
   PubMed Web of Science ®Google Scholar
• Stoecker C, Kim L, Gierke R, et al. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 Years and older in the United States. J Gen Intern Med. 2016;31(8):901–908.
   PubMed Web of Science ®Google Scholar
• Stoecker C, Kobayashi M, Matanock A, et al. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020;38(7):1770–1777.
   PubMed Web of Science ®Google Scholar
• Latifi-Navid H, Latifi-Navid S, Mostafaiy B, et al. Pneumococcal disease and the effectiveness of the PPV23 vaccine in adults: a two-stage bayesian meta-analysis of observational and RCT reports. Sci Rep. 2018;8(1):11051.
   PubMedGoogle Scholar
• Tin Htar M T, Stuurman AL, Ferreira G, et al. Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLOS ONE. 2017;12(5):e0177985.
   PubMed Web of Science ®Google Scholar
• Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114–1125.
   PubMed Web of Science ®Google Scholar
• Ramsay M. The Green Book for immunisation against infectious disease: chapter 25, Pneumococcal. Public Health England. 2020.
   Google Scholar
• UK Health Security Agency. Pneumococcal Polysaccharide Vaccine (PPV) coverage report, England, April 2019 to March 2020. Health Prot Rep. 2020;15(19).
   Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–543.
   PubMed Web of Science ®Google Scholar
• Adler H, German EL, Mitsi E, et al. Experimental human pneumococcal colonization in older adults is feasible and safe, not immunogenic. Am J Respir Crit Care Med. 2021;203(5):604–613.
   PubMed Web of Science ®Google Scholar
• Andrews NJ, Waight PA, George RC, et al. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30(48):6802–6808.
   PubMed Web of Science ®Google Scholar
• Collins AM, Wright AD, Mitsi E, et al. First human challenge testing of a pneumococcal vaccine. double-blind randomized controlled trial. Am J Respir Crit Care Med. 2015;192(7):853–858.
   PubMed Web of Science ®Google Scholar
• German EL, Solórzano C, Sunny S, et al. Protective effect of PCV vaccine against experimental pneumococcal challenge in adults is primarily mediated by controlling colonisation density. Vaccine. 2019;37(30):3953–3956.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013;31(35):3594–3602.
   PubMed Web of Science ®Google Scholar
• Jochems SP, Weiser JN, Malley R, et al. The immunological mechanisms that control pneumococcal carriage. PLoS Pathog. 2017;13(12):e1006665.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics (UK). 2018-based National Population Projections. 2019.
   Google Scholar
• van Hoek Aj, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012;65(1):17–24.
   PubMed Web of Science ®Google Scholar
• Campling J, Jones D, Chalmers JD, et al. The impact of certain underlying comorbidities on the risk of developing hospitalised pneumonia in England. Pneumonia. 2019;11(1):4.
   Web of Science ®Google Scholar
• Stoecker C Economic Assessment of PCV15 & PCV20. Meeting of the ACIP: 2021 Jun 25; Virtual.
   Google Scholar
• Mangen MJ, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015;46(5):1407–1416.
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Huebner RE, et al. A Trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349(14):1341–1348.
   PubMed Web of Science ®Google Scholar
• French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-Infected adults. N Engl J Med. 2010;362(9):812–822.
   PubMed Web of Science ®Google Scholar
• Patterson S, Webber C, Patton M, et al. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials Vaccinol. 2016;5:92–96.
   Google Scholar
• Lawrence H, Pick H, Baskaran V, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: a case-control test-negative design study. PLoS Med. 2020;17(10):e1003326.
   PubMed Web of Science ®Google Scholar
• Department of Health. NHS reference costs 2019 to 2020. 2021.
   Google Scholar
• Joint Formul Comm British Nat Formul. 2017.
   Google Scholar
• MIMS Database. 2022.
   Google Scholar
• NHS England. Directed enhanced service specification: seasonal influenza and pneumococcal polysaccharide vaccination program 2019/20. 2019 Mar 29.
   Google Scholar
• Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539–545.
   PubMed Web of Science ®Google Scholar
• Mangen M-J-J, Huijts SM, Bonten MJM, et al. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17(1):208.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. Code of Practice June 2013.
   Google Scholar
• Essink B, Sabharwal C, Cannon K, et al. Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged ≥18 years. Clinl Infect Dis. 2022;75(3):390–398.
   PubMed Web of Science ®Google Scholar
• Joint Committee on Vaccination and Immunisation. Minutes of the meeting on 2015 Oct 07.
   Google Scholar
• Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–117.
   PubMed Web of Science ®Google Scholar
• Matanock A, Lee G, Gierke R, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):1069–1075.
   PubMed Web of Science ®Google Scholar
• Leidner AJ Summary of three economic models assessing pneumococcal vaccines in US adults. Pneumococcal Vaccines. Meeting of the ACIP: September 29, 2021; Atlanta, GA.
   Google Scholar
• Sun X, Douiri A, Gulliford M. Pneumonia incidence trends in UK primary care from 2002 to 2017: population-based cohort study. Epidemiol Infect. 2019;147:e263.
   PubMed Web of Science ®Google Scholar
• Campling J, Jones D, Chalmers J, et al. Clinical and financial burden of hospitalised community-acquired pneumonia in patients with selected underlying comorbidities in England. BMJ Open Respir Res. 2020;7(1):e000703.
   PubMed Web of Science ®Google Scholar
• Hughes GJ, Wright LB, Chapman KE, et al. Serotype-specific differences in short- and longer-term mortality following invasive pneumococcal disease. Epidemiol Infect. 2016;144(12):2654–2669.
   PubMed Web of Science ®Google Scholar
• Rodrigo C, Bewick T, Sheppard C, et al. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia. Eur Respir J. 2015;45(6):1632–1641.
   PubMed Web of Science ®Google Scholar
• van Hoek AJ, Miller E . Cost-effectiveness of vaccinating immunocompetent ≥65 year olds with the 13-valent pneumococcal conjugate vaccine in England. PLOS ONE. 2016;11(2):e0149540.
   PubMed Web of Science ®Google Scholar
• Shi T, Denouel A, Tietjen AK, et al. Global and regional burden of hospital admissions for pneumonia in older adults: a systematic review and meta-analysis. J Infect Dis. 2019;222(Supplement_7):S570–S576.
   Google Scholar
• Vyse A, Campling J, Czudek C, et al. A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. Expert Rev Vaccines. 2021;20(10):1311–1325.
   PubMed Web of Science ®Google Scholar
• McLaughlin JM, Jiang Q, Gessner BD, et al. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: a systematic review and pooled analysis. Vaccine. 2019;37(43):6310–6316.
   PubMed Web of Science ®Google Scholar
• Sings HL, De Wals P, Gessner BD, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies. Clinl Infect Dis. 2018;68(12):2135–2143.
   Web of Science ®Google Scholar
• Gessner BD, Jiang Q, Van Werkhoven CH, et al. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. Vaccine. 2019;37(30):4147–4154.
   PubMed Web of Science ®Google Scholar
• Sisk JE, Whang W, Butler JC, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–968.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Zimmerman RK, Lin CJ, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine. 2008;26(11):1420–1431.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Dhoubhadel BG, Ishifuji T, et al. Serotype-specific effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumococcal pneumonia in adults aged 65 years or older: a multicentre, prospective, test-negative design study. Lancet Infect Dis. 2017;17(3):313–321.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. Jan 2022.
   Google Scholar
• Public Health England. Pneumococcal polysaccharide vaccine: change to the supply route from. Jun 2021.
   Google Scholar
• Lim WS, Lawrence H. National audit report: adult community-acquired pneumonia audit 2018-2019. Brit Thoracic Soc. 2019;10(4).
   Google Scholar
• Ostermann H, Garau J, Medina J, et al. Resource use by patients hospitalized with community-acquired pneumonia in Europe: analysis of the REACH study. BMC Pulm Med. 2014;14(1):36.
   PubMedGoogle Scholar
• Sandmann FG, Davies NG, Vassall A, et al. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis. 2021;21(7):962–974.
   PubMed Web of Science ®Google Scholar
• Sandmann FG, Shallcross L, Adams N, et al. Estimating the hospital burden of norovirus-associated gastroenteritis in England and its opportunity costs for nonadmitted patients. Clinl Infect Dis. 2018;67(5):693–700.
   PubMed Web of Science ®Google Scholar
• Sandmann FG, Robotham JV, Deeny SR, et al. Estimating the opportunity costs of bed-days. Health Econ. 2018;27(3):592–605.
   PubMed Web of Science ®Google Scholar
• Bloom DE, Brenzel L, Cadarette D, et al. Moving beyond traditional valuation of vaccination: needs and opportunities. Vaccine. 2017;35:A29–A35.
   PubMed Web of Science ®Google Scholar
• Jit M, Hutubessy R. Methodological challenges to economic evaluations of vaccines: is a common approach still possible? Appl Health Econ Health Policy. 2016;14(3):245–252.
   PubMed Web of Science ®Google Scholar
• Brueggemann AB, Jansen van Rensburg MJ, Shaw D, et al. Changes in the incidence of invasive disease due to streptococcus pneumoniae, haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the invasive respiratory infection surveillance initiative: a prospective analysis of surveillance data. Lancet Digital Health. 2021;3(6):e360–e370.
   PubMedGoogle Scholar
• Eden J-S, Sikazwe C, Xie R, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat Commun. 2022;13(1):2884.
   PubMed Web of Science ®Google Scholar
• Fourgeaud J, Toubiana J, Chappuy H, et al. Impact of public health measures on the post-COVID-19 respiratory syncytial virus epidemics in France. Eur J Clin Microbiol Infect Dis. 2021;40(11):2389–2395.
   PubMed Web of Science ®Google Scholar
• Hsu H-T, Huang F-L, Ting P-J, et al. The epidemiological features of pediatric viral respiratory infection during the COVID-19 pandemic in Taiwan. J Microbiol Immunol Infect. 2021. DOI:10.1016/j.jmii.2021.09.017.
   Google Scholar
• Lavoie PM, Reicherz F, Solimano A, et al. Potential resurgence of respiratory syncytial virus in Canada. Can Med Assoc J. 2021;193(29):E1140.
   Web of Science ®Google Scholar
• Olsen SJ, Winn AK, Budd AP, et al. Changes in influenza and other respiratory virus activity during the COVID-19 PANDEMIC - United States, 2020-2021. MMWR Morb Mortal Wkly Rep. 2021;70(29):1013–1019.
   PubMed Web of Science ®Google Scholar
• UK Health Security Agency. Pneumococcal disease: cases caused by strains covered by Prevenar 13 vaccine 2021. [cited 2021 Dec 15]. Available from: https://www.gov.uk/government/publications/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine/pneumococcal-disease-cases-caused-by-strains-covered-by-prevenar-13-vaccine
   Google Scholar
• Casanova C, Küffer M, Leib SL, et al. Re-emergence of invasive pneumococcal disease (IPD) and increase of serotype 23B after easing of COVID-19 measures, Switzerland, 2021. Emerg Microbes Infect. 2021;10(1):2202–2204.
   PubMed Web of Science ®Google Scholar
• Perniciaro S, van der Linden M, Weinberger DM. Re-emergence of invasive pneumococcal disease in germany during the spring and summer of 2021. Clinl Infect Dis. 2022;75(7):1149–1153.
   PubMed Web of Science ®Google Scholar
• Baker RE, Park SW, Yang W, et al. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Nat Acad Sci. 2020;117(48):30547.
   PubMed Web of Science ®Google Scholar
• Privor-Dumm LA, Poland GA, Barratt J, et al. A global agenda for older adult immunization in the COVID-19 era: a roadmap for action. Vaccine. 2021;39(37):5240–5250.
   PubMed Web of Science ®Google Scholar